Anya Biopharm, Inc. · TPEX:7776
Anya Biopharm — CPhI 2022
11 slides from Anya Biopharm's conference presentation, September 2022
Slide 1: Therapeutics — $200+ bn, fast-growing market
therapeutics — $200+ bn, fast-growing market om Mostly administrated parenteral (injections) but patients prefer w ANYA offers solution — A custom tool to employ any biologic compound in oral solid dose format medicines Commercially available and cost-effective Three highly promising candidates deve
Slide 2: Oral Peptides & mAbs: Our target market
Oral Peptides & mAbs: Our target market Small Molecules Peptides Monoclonal Antibodies Peptides are amino acid chains mAbs are man made proteins Chemical compounds of up to ~50 amino acids that act like human antibodies Over 2000 approved drugs Over 60 approved peptides Over 75 approved mAbs Less ta
Slide 3: Four main challenges in oral delivery
Four main challenges in oral delivery… Hostile stomach environment 1 Protease activity in the intestine 2 • An acidic environment in stomach • Proteases like Trypsin and can lead to denaturation of proteins Chymotrypsin break down proteins • Pepsin present in stomach breaks in the intestine down pep
Slide 4: …are very effectively overcome by ANYA
…are very effectively overcome by ANYA Enteric coating 1 MIRA/JE® 2 Strong patent protection available • Enteric coating remains intact in • Our MIRA technology shows very stomach’s acidic environment, swift reduction in activity of degrades in near neutral pH Proteases environment of intestines • M
Slide 5: MIRA/JE flexibility
1 MIRA/JE® flexibility Every biologic is unique Customization is critical MIRA is the answer • Broken by different proteases • Customized protease inhibition • 30 combinations to choose from • Time taken to break varies • Fast vs. slow acting inhibitors • Custom solution for every biologic Multiple
Slide 6: Simple and scalable
2 Simple and scalable Simple excipients All substances used in the oral delivery technology are GRAS approved Fast scale up Predictable and fast scale up, go to market Easy to and commercialization manufacture Solid oral formulation only, significantly higher availability of GMP approved facilities
Slide 7: Best in class technology
3 Best in class technology 28.8% Insulin 5-8% 5-10% 4 fold Increase in bioavailability compared to <Company A> and Company A Company B MIRAJe <Company B> 4.0% Teriparatide 2.1% 1.2% 3.5 & 2 fold Increase in bioavailability MIRA/JE® compared to <Company C> and <Company D> Company C Company D MIRAJe 5
Slide 8: Pipeline
Pipeline 25 bn ANY00X • Potential candidates: 11 bn IL-1,IL-2, IL-6, ANY003 IL-17, IL-23, Sclerostin, • TNF Alfa Inhibitor RANKL, BAFF 11bn ANY004 peptide • Tirzepatide • Rheumatoid arthritis, • Diabetes Psoriatic arthritis, ANY002 • 505b2 Psoriasis • Semaglutide • Formulation studies • NCE • Diabet
Slide 9: Publication
Publication International Journal of Peptide Research and Therapeutics https://doi.org/10.1007/s10989-021-10293-x ® Cheek for updates Oral Delivery of Peptide Formulations and Their Cellular Evaluation Saurabh Patil’ - Kritika Gupta? - Ashish Pandit! - Bhushan Desai? - Siegfried Gschliesser® - Praja
Slide 10: Patent
Patent Canada - CA3072864 China - CN109843274A US - US20200121796A1 India - IN201711033555 EU - EP3509573A1 Eurasia - EA202090317 Singapore - 11201901402P Australia - AU2018336135 Taiwan - 201919683 New Zealand - NZ760995 Brazil - BR112020005363A2 South Africa - ZA202001393A Mexico - MX/a/2020/00243
Slide 11: Contact Us!
CONTACT US ! Bhushan Desai: [email protected]